Market Currents
Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its...
-
Monday, October 15, 2012, 12:58 PM ETAbbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 2 comments: